CEACAM5 and neoplasm: Since NY‐ESO‐1 antibodies are produced in the immune response against malignant tumors expressing the NY‐ESO‐1 antigen, the NY‐ESO‐1 antibody may be a new tumor marker with a completely different mechanism from CEA and CA19‐9, which are tumor expression factors.